DrugPatentWatch Database Preview
Selpercatinib - Generic Drug Details
» See Plans and Pricing
What are the generic sources for selpercatinib and what is the scope of freedom to operate?
Selpercatinib
is the generic ingredient in one branded drug marketed by Loxo Oncology Inc and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Selpercatinib has thirty-six patent family members in twenty-four countries.
One supplier is listed for this compound.
Summary for selpercatinib
| International Patents: | 36 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 11 |
| Clinical Trials: | 5 |
| Patent Applications: | 19 |
| DailyMed Link: | selpercatinib at DailyMed |
Recent Clinical Trials for selpercatinib
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Eli Lilly and Company | Phase 2 |
| Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for selpercatinib
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncology Inc | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Loxo Oncology Inc | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-002 | May 8, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Loxo Oncology Inc | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Loxo Oncology Inc | RETEVMO | selpercatinib | CAPSULE;ORAL | 213246-001 | May 8, 2020 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for selpercatinib
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20190076976 | Start Trial |
| Australia | 2018348161 | Start Trial |
| South Korea | 102143899 | Start Trial |
| Australia | 2017342022 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
